Lansoprazole Almus Pharma

Lansoprazole, the active ingredient in Lansoprazole Almus Pharma, is a proton pump inhibitor presented as an oral dosage form for systemic use. It reduces gastric acid production and is employed in the management of gastro‑oesophageal reflux disease, erosive esophagitis, peptic ulcer disease and Helicobacter pylori eradication regimens.

GNH USA supplies Lansoprazole Almus Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics across global markets.

Lansoprazole is a proton pump inhibitor used to treat conditions related to excess gastric acid secretion. - Gastroesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. - Erosive esophagitis: accelerates mucosal healing and reduces recurrence of lesions. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence by maintaining a low‑acid environment. - Helicobacter pylori eradication (as part of combination therapy): enhances the effectiveness of antibiotic regimens by suppressing gastric acid.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually self‑limiting. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased gas production.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea, abdominal cramping. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: signs of hepatic dysfunction.

Before prescribing Lansoprazole, clinicians should consider several precautionary measures to ensure safe use. - Assess renal and hepatic function: dose adjustment may be required in severe impairment. - Review current medications: potential interactions with antiplatelet agents and antifungals. - Evaluate for osteoporosis risk: long‑term therapy may affect calcium absorption. - Monitor for infection signs: prolonged acid suppression can increase gastrointestinal infection risk. - Use in pregnancy and lactation only if clearly needed: limited data are available. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lansoprazole can alter the pharmacokinetics of several drugs, necessitating careful management of concomitant therapy.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Methotrexate: increased serum levels, watch for toxicity. - Digoxin: higher plasma concentrations, consider dose adjustment. - Iron supplements: reduced absorption, separate dosing by at least 2 hours.